The PRC1 Polycomb group complex interacts with PLZF/RARA to mediate leukemic transformation

  1. Hanane Boukarabila1,2,3,10,
  2. Andrew J. Saurin4,5,10,12,
  3. Eric Batsché6,
  4. Noushine Mossadegh1,2,3,
  5. Maarten van Lohuizen7,
  6. Arie P. Otte8,
  7. Jacques Pradel4,5,9,
  8. Christian Muchardt6,
  9. Michael Sieweke1,2,3,9 and
  10. Estelle Duprez1,2,3,9,11
  1. 1Centre d'Immunologie de Marseille-Luminy (CIML), Université de la Méditerranée, Campus de Luminy, 13288 Marseille Cedex 09, France;
  2. 2Institut National de la Santé et de la Recherche Médicale (INSERM) U631, 13288 Marseille, France;
  3. 3Centre National de la Recherche Scientifique (CNRS), UMR 6102, 13288 Marseille, France;
  4. 4Institut de Biologie du Développement de Marseille Luminy, Université de la Méditerranée, Campus de Luminy, 13288 Marseille Cedex 09, France;
  5. 5Centre National de la Recherche Scientifique (CNRS), UMR 6216, 13288 Marseille, France;
  6. 6Unit of Epigenetic Regulation Avenir INSERM, URA2578 CNRS Institut Pasteur, 75015 Paris, France;
  7. 7Division of Molecular Genetics, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands;
  8. 8Swammerdam Institute for Life Sciences, University of Amsterdam, 1098 SM Amsterdam, The Netherlands
    1. 10

      10 These authors contributed equally to this work.

    Abstract

    Ectopic repression of retinoic acid (RA) receptor target genes by PML/RARA and PLZF/RARA fusion proteins through aberrant recruitment of nuclear corepressor complexes drives cellular transformation and acute promyelocytic leukemia (APL) development. In the case of PML/RARA, this repression can be reversed through treatment with all-trans RA (ATRA), leading to leukemic remission. However, PLZF/RARA ectopic repression is insensitive to ATRA, resulting in persistence of the leukemic diseased state after treatment, a phenomenon that is still poorly understood. Here we show that, like PML/RARA, PLZF/RARA expression leads to recruitment of the Polycomb-repressive complex 2 (PRC2) Polycomb group (PcG) complex to RA response elements. However, unlike PML/RARA, PLZF/RARA directly interacts with the PcG protein Bmi-1 and forms a stable component of the PRC1 PcG complex, resulting in PLZF/RARA-dependent ectopic recruitment of PRC1 to RA response elements. Upon treatment with ATRA, ectopic recruitment of PRC2 by either PML/RARA or PLZF/RARA is lost, whereas PRC1 recruited by PLZF/RARA remains, resulting in persistent RA-insensitive gene repression. We further show that Bmi-1 is essential for the PLZF/RARA cellular transformation property and implicates a central role for PRC1 in PLZF/RARA-mediated myeloid leukemic development.

    Keywords

    Footnotes

    • 9

      9 These authors are considered cosenior authors.

    • 11

      11 Corresponding authors.

      E-MAIL eduprez{at}ciml.univ-mrs.fr; FAX 33(0)49126919430.

    • 12

      12 E-MAIL saurin{at}ibdml.univ-mrs.fr; FAX 33(0)491820682.

    • Article is online at http://www.genesdev.org/cgi/doi/10.1101/gad.512009.

    • Supplemental material is available at http://www.genesdev.org.

      • Received October 28, 2008.
      • Accepted April 3, 2009.
    | Table of Contents

    Life Science Alliance